Bank of Montreal Can increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 342.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 188,828 shares of the biopharmaceutical company’s stock after acquiring an additional 146,147 shares during the quarter. Bank of Montreal Can’s holdings in Regeneron Pharmaceuticals were worth $70,991,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Fieldpoint Private Securities LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $130,000. Virtu KCG Holdings LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $206,000. Vident Investment Advisory LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $200,000. People s United Financial Inc. increased its stake in Regeneron Pharmaceuticals by 656.7% in the 2nd quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 394 shares during the period. Finally, Moors & Cabot Inc. acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $217,000. Institutional investors and hedge funds own 66.63% of the company’s stock.
Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $371.28 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.63 and a quick ratio of 3.07. The company has a market cap of $39,890.00, a P/E ratio of 33.72, a price-to-earnings-growth ratio of 1.42 and a beta of 1.52. Regeneron Pharmaceuticals Inc has a 1 year low of $340.09 and a 1 year high of $543.55.
REGN has been the topic of several research reports. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, November 27th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $480.00 to $380.00 in a research note on Friday, December 1st. Robert W. Baird upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Friday, November 3rd. Argus dropped their price objective on shares of Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a research note on Thursday, December 28th. Finally, Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $471.11.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.